191 related articles for article (PubMed ID: 18287889)
1. Use of nebivolol for the treatment of endothelial dysfunction in patients with hypertension: the EDEN registry.
Masoli O; Redruello M; Baliño NP; Grynberg L; Sonia T; Collaud C; Md LV
J Cardiovasc Pharmacol; 2008 Feb; 51(2):202-7. PubMed ID: 18287889
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Tzemos N; Lim PO; MacDonald TM
Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol: a third-generation beta-blocker for hypertension.
Cheng JW
Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
[TBL] [Abstract][Full Text] [Related]
4. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension.
Pronko TP; Zinchuk VV
Clin Physiol Funct Imaging; 2009 May; 29(3):170-6. PubMed ID: 19170724
[TBL] [Abstract][Full Text] [Related]
5. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
7. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
von Fallois J; Faülhaber HD
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
[TBL] [Abstract][Full Text] [Related]
8. [Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].
Gromnatskiĭ NI; Dius'mikeeva NB
Kardiologiia; 2002; 42(10):27-30. PubMed ID: 12494053
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol: impact on cardiac and endothelial function and clinical utility.
Toblli JE; DiGennaro F; Giani JF; Dominici FP
Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
[TBL] [Abstract][Full Text] [Related]
10. Does nebivolol improve endothelial dysfunction and will it rescue the reputation of the beta-blockers in the future?
Celik T; Iyisoy A
Anadolu Kardiyol Derg; 2007 Dec; 7(4):388-9. PubMed ID: 18065334
[No Abstract] [Full Text] [Related]
11. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes].
Makolkin VI; Akhmedova OO; Buval'tsev VI; Gavrilov IuV; Petriĭ VV
Kardiologiia; 2003; 43(2):40-3. PubMed ID: 12891271
[TBL] [Abstract][Full Text] [Related]
12. The antihypertensive and cardiac hemodynamic effects of nebivolol.
DeCrée J; Van Rooy P; Geukens H; Haeverans K; Verhaegen H
Angiology; 1992 May; 43(5):369-77. PubMed ID: 1348916
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
Germino FW; Lin Y; Pejović V; Bowen L
Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
[TBL] [Abstract][Full Text] [Related]
18. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension.
Korkmaz H; Karaca I; Koç M; Onalan O; Yilmaz M; Bilen MN
Endothelium; 2008; 15(3):149-55. PubMed ID: 18568956
[TBL] [Abstract][Full Text] [Related]
19. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Merchant N; Searles CD; Pandian A; Rahman ST; Ferdinand KC; Umpierrez GE; Khan BV
J Clin Hypertens (Greenwich); 2009 Dec; 11(12):720-5. PubMed ID: 20021529
[TBL] [Abstract][Full Text] [Related]
20. Effects of the systemic beta-adrenoceptor antagonist nebivolol on ocular hemodynamics in glaucoma patients.
Zeitz O; Galambos P; Matthiesen N; Wagenfeld L; Schillinger W; Wiermann A; Richard G; Klemm M
Med Sci Monit; 2008 May; 14(5):CR268-275. PubMed ID: 18443551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
